Document is current
Any future updates will be listed below
-
Authors
De Marco, Margot https://orcid.org/0000-0003-4134-1437
Gauttier, Vanessa
Pengam, Sabrina
Mary, Caroline
Ranieri, Bianca
Basile, Anna
Festa, Michela
Falco, Antonia
Reppucci, Francesca
Cammarota, Anna Lisa
Acernese, Fausto https://orcid.org/0000-0003-3103-3473
De Laurenzi, Vincenzo
Sala, Gianluca https://orcid.org/0000-0002-4494-915X
Brongo, Sergio
Miyasaka, Masayuki
Shalapour, Shabnam https://orcid.org/0000-0002-4743-3706
Vanhove, Bernard
Poirier, Nicolas
Iaccarino, Roberta
Karin, Michael
Turco, Maria Caterina https://orcid.org/0000-0002-7835-359X
Rosati, Alessandra https://orcid.org/0000-0001-6675-0857
Marzullo, Liberato
-
Funding
Funding for this research was provided by:
Fondazione Italiana per la Ricerca sul Cancro (AIRC IG-18534)
Fondazione Italiana per la Ricerca sul Cancro (AIRC IG-20043)
Regione Campania (POR FESR Regione Campania 2014-2020)
Regione Campania (POR FESR Regione Campania 2014-2020)
Regione Campania (POR FESR Regione Campania 2014-2020)
- License Information
-
More Information
Article History
Received: 20 July 2021
Revised: 9 December 2021
Accepted: 4 January 2022
First Online: 3 March 2022
Competing interests
: VG, SP, CM, BV, and NP are employees and shareholders of OSE Immunotherapeutics, a biotechnology company developing SIRPĪ± antagonists (NCT03990233). MDM, AB, MF, AF, VDL, MCT, AR, and LM are shareholders of BIOUNIVERSA s.r.l. that provided anti-BAG3 antibodies. The remaining authors declare no conflict of interest.
